ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed the conversion and listing of 120,463,260 Unlisted Shares into H Shares, which will start trading on The Stock Exchange of Hong Kong Limited on September 5, 2024. This major shift in the company’s share structure has resulted in H Shares now constituting 93.28% of the total share capital, significantly up from the previous 61.08%. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
